Conditions: Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Keywords: GIOP, Glucocorticoid, osteporosis, denosumab, BMD, Bone Mineral Density
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 795
Healthy volunteers: no

Brief summary:
This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.

Detailed description:

Arms:
arm 1: Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months. arm 2: Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.

Interventions: intervention 1: Denosumab intervention 2: Placebo for risendronate intervention 3: Risendronate intervention 4: Placebo for denosumab
Intervention descriptions: intervention 1: Administered by subcutaneous injection once every 6 months intervention 2: Administered orally once a day intervention 3: Administered orally once a day intervention 4: Administered by subcutaneous injection once every 6 months

Protocol document: